In 2019, world renowned scientific pioneers and diagnostic veterans came together with a shared belief that bringing the power of CRISPR and synthetic biology to diagnostic development could improve human health. Leveraging an intellectual property portfolio assembled from foundational technologies developed at the Broad Institute and Harvard University’s Wyss Institute, the team founded Sherlock Biosciences to transform these scientific breakthroughs into commercially available products that will make rapid, accurate and affordable diagnostic tests accessible to people at the point of need.
Today, Sherlock continues to disrupt diagnostics, envisioning a world where everyone has access to accurate, actionable health information wherever and whenever it is needed.
